1. SGLT2 inhibitors protect cardiomyocytes from myocardial infarction: a direct mechanism?
   Jian Zhang et al, 2022, Future Cardiology CrossRef
2. Effect of Dapagliflozin on Patients with Rheumatic Heart Disease Mitral Stenosis
   An Aldia Asrial et al, 2023, Journal of Clinical Medicine CrossRef
3. Coinfection of Dermal Fibroblasts by Human Cytomegalovirus and Human Herpesvirus 6 Can Boost the Expression of Fibrosis-Associated MicroRNAs
   Irene Soffritti et al, 2023, Microorganisms CrossRef
4. Empagliflozin mitigates cardiac hypertrophy through cardiac RSK/NHE-1 inhibition
   Sha Chen et al, 2024, Biomedicine & Pharmacotherapy CrossRef
5. The interaction between non-coding RNAs and SGLT2: A review
   Joanna Jarosz-Popek et al, 2024, International Journal of Cardiology CrossRef
6. Molecular mechanism of triptolide in myocardial fibrosis through the Wnt/β-catenin signaling pathway
   Yiwen Zhang et al, 2024, Scandinavian Cardiovascular Journal CrossRef
7. Doxorubicin‑induced cardiomyopathy is mitigated by empagliflozin via the modulation of endoplasmic reticulum stress pathways
   Akshi Malik et al, 2024, Molecular Medicine Reports CrossRef